DKSH Singapore and Novartis Announce Strategic Partnership to Support Access to Ophthalmology Solutions in Singapore

DKSH have entered into a strategic partnership with Novartis to support access to Novartis' ophthalmology portfolio in Singapore, and the availability of eye care solutions for healthcare professionals and patients.

Singapore, October 8, 2026 - DKSH Singapore's Business Unit Healthcare, a leading partner for companies seeking to grow their healthcare business in Asia and beyond, and Novartis have entered into a strategic partnership to support access to Novartis' ophthalmology portfolio in Singapore. By leveraging DKSH Healthcare's commercial and distribution capabilities, the partnership aims to support healthcare professionals and facilitate patient access to ophthalmology treatments.

As Singapore continues its focus on preventive healthcare and healthy ageing, maintaining good eye health is increasingly important, particularly as the population ages. Vision impairment can affect daily activities and quality of life, underscoring the importance of early detection, timely intervention and ongoing care. Through this partnership, Novartis and DKSH Singapore aim to support healthcare professionals and facilitate access to ophthalmology care for patients in Singapore.

Under the partnership, DKSH Singapore will provide agency services for Novartis' ophthalmology portfolio in Singapore, covering sales and marketing, credit and collection, and distribution activities.

"At Novartis, we are committed to reimagining medicine and improving outcomes for patients. We are pleased to partner with DKSH. Its healthcare network and local expertise will help support access to our ophthalmology portfolio and reinforce our commitment to patients and healthcare professionals in Singapore," said Poh Hwee Tee, Country President, Novartis Singapore.

"We are honored to collaborate with Novartis, a global leader in healthcare innovation. At DKSH Healthcare, we work across the healthcare value chain to support the reliable, compliant and sustainable delivery of healthcare solutions, drawing on our scale, local expertise and execution capabilities, and advancing our commitment to 'Healthcare for All'. Together with Novartis, we aim to support access to quality ophthalmology solutions through a strong partnership and disciplined execution," said Reuben Ong, Vice President, Business Unit Healthcare, DKSH Singapore.

As healthcare needs continue to evolve, both organizations remain committed to working closely with healthcare stakeholders to support access to ophthalmology care and contribute positively to Singapore's healthcare ecosystem.

About Novartis

Novartis is an innovative medicines company. Every day, the company works to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Novartis medicines reach nearly 300 million people worldwide. www.novartis.com/sg-en/

About DKSH
For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,580 specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025. www.dksh.com/hec